GlaxoSmithKline, the pharmaceutical company that makes Excedrin, has announced that two of their products are temporarily discontinued “out of an abundance of caution.”
The company is suspending production of Excedrin Extra Strength and Excedrin Migraine pending further investigation.
In a statement to CNN, GlaxoSmithKline explained the reason for the sudden discontinuing of the products.
“Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs, and Excedrin Migraine Caplets and Geltabs.
“We are working hard to resolve the issue as quickly as possible, but at this point in time cannot confirm a definite date as to when supply will resume,” the company continued.
“Other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product.”
The two discontinued products, the company insists, don’t pose a direct risk to consumers. They suspended production out of an abundance of caution in order to prevent any future issues down the line.
The company states they can remedy the issue quickly.
GlaxoSmithKline has not issued a recall for the affected products. This suggests they truly don’t believe the products pose a direct threat to consumers.
Regardless, consumers should still avoid Excedrin Extra Strength and Excedrin Migraine. Wait until more information has been made public before continuing use. If the issue affects the dosage of the medication, you might inadvertently consume a larger dose than is safe.
It is strange that a company as large as GlaxoSmithKline would discontinue the production and distribution of two of its products without issuing a full-scale recall.
In the meantime, however, the company insists that its other pain relief medication products are safe for consumers, and remain in production.
